Psoriatic Arthritis screening and treatment by Dermatological practitioner

• Conditions: MODERATE TO SEVERE PSORIASISPsoriatic Arthropathy; Arthropathic psoriasis; L40.5

• Registration Number: DRKS00017002
• Lead Sponsor: AbbVie Deutschland GmbH & Co. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-12-27
• Study Start: 2019-08-06
• Results First Posted: 2023-10-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 407

Inclusion Criteria

Adult patients >= 18 years
- Moderate to severe plaque-psoriasis
- Currently on systemic psoriasis treatment
- Either suspicion of joint involvement or diagnosed PsA

Exclusion Criteria

- Patients with non-plaque psoriasis
- Patients not on systemic treatment
- Patients not willing or able to give written informed consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective of the study is to describe the implementation of screening tools and monitoring measures for PsA in dermatological centers.<br><br>Execution of screening:<br>Proportion of centers using the following screening measures<br>- Predictors (e.g. nail involvement)<br>- Screening questionnaires<br>- Patient interviews<br>- Physical examination<br>- Imaging procedures<br><br>For patients with diagnosed PsA:<br>a) Proportion of sites that are informed about <br>- characteristics of PsA<br>b) Proportion of sites that monitor (regularly):<br>- laboratory parameters <br>- disease activity<br>- functional impairment<br>- radiographic status

Secondary Outcome Measures

Name	Time	Method
Secondary objectives are: <br>1.) To identify the extent and preferences for various procedures performed by different dermatological sites related to patient care of PsA-patients and <br>2.) To uncover patient characteristics